Project Grant HT94252310364
Award Date
7/1/23
Completion Date
6/30/27
Dollars Obligated
$785K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Newark, NJ 07107, USA
Similar Awards
The Defense Health Agency awarded Rutgers, The State University a $471,000 project grant under the Military Medical Research and Development program (CFDA 12.420) to develop new therapeutic strategies for chemo brain in ovarian cancer survivors. The grant period runs from July 1, 2023 through June 30, 2027 in New Brunswick, New Jersey. Through its Research Financial Services division, Rutgers will leverage its expertise in bioengineering and disease research to investigate medical solutions...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...
Rutgers The State University of New Jersey, doing business as Rbhs-School of Nursing, was awarded a $783,077 Project Grant from the Defense Health Agency on May 1, 2023 to complete the project by April 30, 2026. The grant supports research titled "Defining the Cell Cycle Phase-Specific Regulation and Function of MTORC1 to Identify New Therapeutic Targets in TSC Tumors" under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and...
The Defense Health Agency awarded a $250,000 Project Grant to Rutgers, The State University of New Jersey to conduct research titled "BOOSTING MYELINATION USING VISUAL FLICKER IN THE ACUTE CUPRIZONE INTOXICATION MODEL". The grant, funded under the Military Medical Research and Development program (CFDA 12.420), will support research to investigate medical solutions for the battlefield through basic, applied, and advanced biomedical research. The project is scheduled to be completed...
This federal Project Grant award of $785,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports mechanism-centric predictive modeling research for prostate cancer at Rutgers, The State University of New Jersey. The research aims to develop innovative approaches for improving diagnosis, treatment, and outcomes for military personnel and the public impacted by prostate cancer. Over the performance period from July 1, 2024...
The Department of the Army Medical Command awarded Rutgers, The State University of New Jersey a $751,587 Project Grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research targeting adenosine kinase for the prevention of post-traumatic epilepsy from September 30, 2022 to September 29, 2025. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public health...
The federal Block Grant award of $824,250 was provided by the Defense Health Agency to Rutgers, The State University of New Jersey, to support the Lung Cancer Research Program. This award, under the Military Medical Research and Development program (CFDA 12.420), will fund innovative biomedical research projects at Rutgers focused on improving health outcomes for military service members, veterans, and the broader public. Rutgers, leveraging its expertise in medicine, nursing, public health, and...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The University of Maryland, Baltimore (UMB) was awarded a $587,271 Project Grant from the Defense Health Agency, under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), to conduct research on "DUAL INHIBITION OF PARP AND IL-6 AS A NOVEL THERAPEUTIC APPROACH FOR BRCA-MUTATED TRIPLE-NEGATIVE BREAST CANCER." This research project will occur from July 1, 2024 to June 30, 2027. The Military Medical Research and Development program supports a...
The Department of the Army Medical Command awarded a $531,300 Project Grant to Hackensack University Medical Center to support research into the role of RUNX1 rearrangements in triple-negative breast cancer progression and immune evasion. The grant was awarded on September 15, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of September 14, 2025. Through this funding, Hackensack University Medical Center will conduct research to...